Renal-protective effect of non-depressor dose of cicletanine in streptozotocin diabetic rats

Journal of Hypertension

Volumn 17, Issue 5, 1999, Pages 695-700

  Kohzuki, Masahiro ^a   Wu, Xue Min ^a   Kamimoto, Masahiro ^a   Yoshida, Kazunori ^a   Watanabe, Mihoko ^a   Hashimoto, Mika ^a   Kanazawa, Masayuki ^b   Saito, Takao ^b   Yasujima, Minoru ^c   Sato, Tokutaro ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Blood pressure; Cicletanine; Proteinuria; Renal function; Wistar Kyoto rats

Indexed keywords

ALBUMIN; CICLETANINE; GLUCOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CAPILLARY PRESSURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; KIDNEY FUNCTION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PARTIAL NEPHRECTOMY; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; URINARY EXCRETION;

EID: 0033055893     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199917050-00014     Document Type: Article

References (36)

1. 1 Mogensen CE. Prediction of clinical diabetic nephropathy in IDDM patients: alternatives to microalbuminuria? Diabetes 1990; 39:761 -767.
2. 2 Viberti G, Mackintosh D, Bilous RW, Pickup JC, Keen H. Proteinuria in diabetes mellitus: a role of spontaneous and experimental variation of glycemia. Kidney Int 1982; 21:714-720.
3. 3 Mathiesen ER, Oxenball B, Johansen K, Svendsen PA, Deckert T. Incipient nephropathy in type I (insulin-dependent) diabetes. Diabetologia 1984; 26:406-410.
4. 4 Kohzuki M. Yasujima M, Kanazawa M, Yoshida K, Liu PF, Obara K, et al. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 1995; 13:97-103.
5. 5 Anderson S, Brenner BM. The critical role of nephron mass and of intraglomerular pressure for initiation and progression of experimental hypertensive-renal disorders. In: Laragh JH, Brenner BM (editors): Hypertension; pathophysiology, diagnosis and management. New York: Raven Press; 1990, pp. 1163-1176.
6. 6 Yoshida K, Kohzuki M, Yasujima M, Kanazawa M, Abe K. Effects of benidipine, a calcium antagonist, on urinary kallikrein excretion and renal impairment in experimental diabetes. J Hypertens 1996; 14:215-222.
7. 7 Malherbe E, Auguet M, Delaflotte S, Priotzky E, Clostre F, Braquet P. Antihypertensive profile of cicletanine, a furopyridine derivative: comparison with captopril, indapamide and prazocin. Pharmacol Res Commun 1988; 20:121-133.
8. 8 Deby C, Bourgain RH, Andries R, Braquet P. Modulation of prostacyclin synthetase by cicletanine and drugs which affect ion transport. Pharmacol Res Commun 1988; 20:101-108.
9. 9 Deby C, Bourgain RH, Dupont G, Pincemail J, Garay R, Braquet P. Modulation of in vitro generation of prostanoids by drugs affecting membrane ion transport. Drugs Exp Clin Res 1988; 14:123-134.
10. 10 Clostre F, Etienne A. General pharmacology of cicletanine. Drugs Exp Clin Res 1988; 14:73-82.
11. 11 Edmond C, Bompart G, Rakotoarivony J, Bascands JL, Pecher C, Adam A, et al. Protective effect of cicletanine on hypertension-induced decreases in the renal kallikrein-kinin and prostaglandin systems in stroke-prone spontaneously hypertensive rats. J Cardiovasc Pharmacol 1992; 20:601-607.
12. 12 Szczepanska-Konkel M, Redlak M, Angielski S. Glibenclamid sensitive K channels are responsible tor angiotensin II hypersensitive contraction and atrial natriuretic factor refractoriness of glomeruli in low-sodium rats. Biochem Biophys Res Commun 1991; 181:871-876.
13. 13 Kohzuki M, Yasujima M, Yoshida K, Kanazawa M, Yoshinaga K, Abe K. The kidney protecting effect of trandolapril in normotensive and hypertensive diabetic rats. Pharmacometrics 1992; 44:309-315.
14. 14 Kohzuki M, Kanazawa M, Liu PF, Yoshida K, Saito T, Yasujima M, et al. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: the chronic effects on cardio-and reno-protection of angiotensin converting enzyme inhibitors. J Hypertens 1995; 13:1785-1790.
15. 15 Saito T, Sumithran E, Glasgow EF, Atkins RC. The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 1987; 32:691-699.
16. 16 Saito T, Sato H, Obara K, Kamakage K, Abe K, Furuyama T, et al. Progression of experimental focal glomerulosclerosis in the spontaneously hypertensive rat J Lab Clin Med 1990; 115:165-173.
17. 17 Grond J, Beukers JY, Schilthuis MS, Weening JJ, Elema JD. Analysis of renal structural and functional features in two rat strains with a different susceptibility to glomerular sclerosis. Lab Invest 1986; 54:77-83.
18. 18 Van Damme B, Koudstaal J. Measuring glomerular diameters in tissue sections. Virchows Arch A Pathol Anat Histopathol 1976; 369:283-291.
19. 19 Ikeda K, Nara Y, Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Anim 1991; 25:26-29
20. 20 Daniels BS, Hostetter TH. Aldose reductase inhibition and glomerular abnormalities in diabetic rats. Diabetes 1989; 38:981-986.
21. 21 Yamamoto J, Nakai M. Effects of moderate diabetes on cardiac performance in spontaneously hypertensive rats and Wistar-Kyoto rats. Hypertension 1988; 11:344-351.
22. 22 Carbonell LF, Salom MG, Garcia-Estan J, Salazar FJ, Ubeda M, Quesada T. Hemodynamic alterations in chronically conscious unrestrained diabetic rats. Am J Physiol 1987; 252;H900-H905.
23. 23 Uehara Y, Numabe A, Hirawa N, Kawabata Y, Iwai J, Ono H, et al. Antihypertensive effects of cicletanine and renal protection in Dahl salt-sensitive rats. J Hypertens 1991; 9:719-728.
24. 24 Zats R, Dunn BR, Meyer TW, Anderson S, Rennke HG, Brenner BM. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77:1925-1930.
25. 25 Johnston CI, Yasujima M, Clappison BH. The kallikrein-kinin system and angiotensin converting enzyme inhibition in hypertension. In: Horovits ZP (editor) : Angiotensin converting enzyme inhibitors - mechanism of action and clinical implications. Baltimore: Urban-Schwarzenberg; 1981, pp. 123-139.
26. 26 Jaffa AA, Miller DH, Bailex GS, Chao J, Margolius HS, Mayfield RK. Abnormal regulation of renal kallikrein in experimental diabetes: effects of insulin on prokallikrein synthesis and activation. J Clin Invest 1987; 80:1651-1659.
27. 27 Mayfield RK, Marholius HS, Bailey GS, Miller DH, Seus DA, Squires J, et al. Urinary and renal tissue kallikrein in the streptozotocin-diabetic rat. Diabetes 1985; 34:22-28.
28. 28 Kon V, Fogo A, Ichikawa I. Bradykinin causes selective efferent arteriolar dilatation during angiotensin I converting enzyme inhibition. Kidney Int 1993; 44:545-550.
29. 29 AlvaresGuerra M, Alda O, Morin E, Allard M, Garay RP. Reduction by (-) cicletanine of the vascular reactivity to angiotensin II in rats. J Cardiovasc Pharmacol 1996; 28:564-570.
30. 30 Uehara Y, Kawabata Y, Hirawa N, Takada S, Nagata T, Numabe A, et al. Possible radical scavenging properties of cicletanine and renal protection in Dahl salt sensitive rats. Am J Hypertens 1993; 6:463-472.
31. 31 Cooper ME, Allen TJ, Macmillan P, Bach L, Jerums G, Doyle AE. Genetic hypertension accelerates nephropathy in the streptozotocin diabetic rat. Am J Hypertens 1988; 1:1-5.
32. 32 Trimble ER, Karakash C, Malaisse-Lagae F, Vassutine L, Renold AE. Effects of intraportal islet transplantation on the transplanted tissue and the recipient pancreas. Functional studies. Diabetes 1980; 29:314-347.
33. 33 ArRajab A, Ahren B. Long-term diabetologic effect of streptozotocin in rats. J Cardiovasc Pharmacol 1993; 8:50-57.
34. 34 Seyer-Hansen K. Renal hypertrophy in experimental diabetes. Kidney Int 1983; 23:643-646.
35. 35 Steffes MW, Brown DM, Mauer SM. Diabetic glomerulopathy following unilateral nephrectomy in the rat. Diabetes 1978; 27:35-41.
36. 36 O'Donneli MP, Kasiske BL, Daniels FX, Keane WF. Effect of nephron loss on glomerular hemodynamics and morphology in diabetic rats. Diabetes 1986; 35:1011-1015.